RIGL News and Press, Rigel Pharmaceuticals Inc. From 05/22/25

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress PR Newswire Final data from the GAVRETO ® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHI...

2025-05-16 22:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-05-09 05:37:08 ET Summary The Biotech industry has underperformed due to Trump administration, RFK Jr's skepticism, and funding uncertainty, with major ETFs down 19-25% over six months. Some biotech companies with approved products and successful rollouts have outperformed, h...

2025-05-07 18:16:40 ET Summary Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operat...

2025-05-06 23:14:22 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Call Transcript Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability Rigel Looks Interesting, But Let's Wait For A Lower Price Rigel Pharmaceutical...

2025-05-06 23:13:47 ET Rigel Pharmaceuticals, Inc. (RIGL) Q1 2025 Earnings Conference Call May 06, 2025, 04:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive...

2025-05-06 16:30:26 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability Rigel Looks Interesting, But Let's Wait For A Lower Price Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript Rigel Pharmaceutical...

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update PR Newswire First quarter 2025 total revenue of approximately $53.3 million , which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million...

Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2025 Standard BioTools Inc. (LAB) is expected to report $-0.06 for Q1 2025 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2025 CF Bankshares Inc. (CFBK) is expected to report for Q1 2025 Jack Henry & A...

2025-05-05 17:20:34 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability Rigel Looks Interesting, But Let's Wait For A Lower Price Rigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call Transcript Rigel settles patent...